These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 11081381)

  • 1. Autologous CD34+ enriched peripheral blood progenitor cell (PBPC) transplantation is associated with higher morbidity in patients with lymphoma when compared to unmanipulated PBPC transplantation.
    Friedman J; Lazarus HM; Koç ON
    Bone Marrow Transplant; 2000 Oct; 26(8):831-6. PubMed ID: 11081381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous CD34+ cell transplantation for patients with advanced lymphoma: effects of overnight storage on peripheral blood progenitor cell enrichment and engraftment.
    Koç ON; Gerson SL; Phillips GL; Cooper BW; Kutteh L; Van Zant G; Reece DE; Fox RM; Schupp JE; Tainer N; Lazarus HM
    Bone Marrow Transplant; 1998 Feb; 21(4):337-43. PubMed ID: 9509966
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autografting of highly purified peripheral blood progenitor cells following myeloablative therapy in patients with lymphoma: a prospective study of the long-term effects on tumor eradication, reconstitution of hematopoiesis and immune recovery.
    Dreger P; Viehmann K; von Neuhoff N; Glaubitz T; Petzoldt O; Glass B; Uharek L; Rautenberg P; Suttorp M; Mills B; Mitsky P; Schmitz N
    Bone Marrow Transplant; 1999 Jul; 24(2):153-61. PubMed ID: 10455343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.
    Tarella C; Di Nicola M; Caracciolo D; Zallio F; Cuttica A; Omedè P; Bondesan P; Magni M; Matteucci P; Gallamini A; Pileri A; Gianni AM
    Bone Marrow Transplant; 2002 Dec; 30(11):725-32. PubMed ID: 12439694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome.
    Lazarus HM; Pecora AL; Shea TC; Koç ON; White JM; Gabriel DA; Cooper BW; Gerson SL; Krieger M; Sing AP
    Bone Marrow Transplant; 2000 Mar; 25(5):559-66. PubMed ID: 10713636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative lymphocyte subset reconstitution after allogeneic hematopoietic transplantation from matched related donors with CD34+ selected PBPC grafts unselected PBPC grafts or BM grafts.
    Behringer D; Bertz H; Schmoor C; Berger C; Dwenger A; Finke J
    Bone Marrow Transplant; 1999 Aug; 24(3):295-302. PubMed ID: 10455369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose therapy with peripheral blood progenitor cell support in patients with non-Hodgkin's lymphoma.
    Haas R; Murea S; Goldschmidt H; Döhner H; Moos M; Witt B; Eugenhart R; Wannenmacher M; Hunstein W
    Stem Cells; 1995 Dec; 13 Suppl 3():28-35. PubMed ID: 8747986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infections after CD34-selected or unmanipulated autologous hematopoietic stem cell transplantation.
    Frère P; Pereira M; Fillet G; Beguin Y
    Eur J Haematol; 2006 Feb; 76(2):102-8. PubMed ID: 16405430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
    Witzens-Harig M; Heilmann C; Hensel M; Kornacker M; Benner A; Haas R; Fruehauf S; Ho AD
    Stem Cells; 2007 Jan; 25(1):228-35. PubMed ID: 17204607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of postengraftment infectious morbidity and mortality after allogeneic partially T cell-depleted peripheral blood progenitor cell transplantation versus T cell-depleted bone marrow transplantation.
    Broers AE; van der Holt B; Haze S; Braakman E; Gratama JW; Löwenberg B; Cornelissen JJ
    Exp Hematol; 2005 Aug; 33(8):912-9. PubMed ID: 16038784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
    Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
    Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
    Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
    Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined bone marrow and peripheral blood progenitor cell autografts for patients with poor mobilization.
    Sinitsyn Y; Malone A; Mandeli J; Grosskreutz C; Osman K; Scigliano E; Shi P; Isola L
    Cytotherapy; 2009; 11(4):457-63. PubMed ID: 19499401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral blood progenitor cell collection without close monitoring of peripheral blood CD34+ cells: A feasible strategy for multiple myeloma or pre-treated Non-Hodgkin's Lymphoma patients mobilized with low-dose cyclophosphamide plus G-CSF.
    Callera F; Cavenaghi L; de Melo CM
    Transfus Apher Sci; 2009 Apr; 40(2):91-5. PubMed ID: 19233728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using at least 5x10(6)/kg CD34+ cells for autologous stem cell transplantation significantly reduces febrile complications and use of antibiotics after transplantation.
    Scheid C; Draube A; Reiser M; Schulz A; Chemnitz J; Nelles S; Fuchs M; Winter S; Wickramanayake PD; Diehl V; Söhngen D
    Bone Marrow Transplant; 1999 Jun; 23(11):1177-81. PubMed ID: 10382958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical applications of CD34(+) peripheral blood progenitor cells (PBPC).
    Vogel W; Scheding S; Kanz L; Brugger W
    Stem Cells; 2000; 18(2):87-92. PubMed ID: 10742380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autologous stem cell transplantation with selected CD34+ cells and unmanipulated peripheral blood stem cells in patients with relapsed and refractory Hodgkin's lymphoma: a single centre experience.
    Ballova V; Ladicka M; Vranovsky A; Lakota J
    Neoplasma; 2008; 55(5):428-36. PubMed ID: 18665754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicities after peripheral blood progenitor cell transplantation for lymphoid malignancies: analysis of 300 cases in a single institution.
    Ketterer N; Sonet A; Dumontet C; Moullet I; Thieblemont C; Espinouse D; Bouafia F; Coiffier B; Salles G
    Bone Marrow Transplant; 1999 Jun; 23(12):1309-15. PubMed ID: 10414921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study.
    Limat S; Woronoff-Lemsi MC; Deconinck E; Racadot E; Jacquet M; Herve P; Cahn JY
    Bone Marrow Transplant; 2000 May; 25(9):997-1002. PubMed ID: 10800070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.